{"transactions":[{"id":939519,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":6000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares of common stock were issued upon conversion as follows:  668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1577119},"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939518,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":22500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares of common stock were issued upon conversion as follows:  2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5914197},"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939517,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock were issued upon conversion as follows:  556,810 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 29,593 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"), 10,988 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"), 119,478 by MPM Oncology Innovations\nFund, L.P. (\"MPM Oncology\") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. (\"MPM Oncology Impact\"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and\nBV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing\nmember of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314262},"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939516,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"purchase","planned":false,"acquired":true,"shares":1112777,"price":18,"value":20029986.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact."}],"balance_after":10260064,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939515,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":1577119,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares of common stock were issued upon conversion as follows:  668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact."}],"balance_after":9147287,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939514,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":5914197,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares of common stock were issued upon conversion as follows:  2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact."}],"balance_after":7570168,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":939513,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":3,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":4,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":5,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":6,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":7,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":8,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:19:26.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":1314262,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock were issued upon conversion as follows:  556,810 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 29,593 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"), 10,988 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"), 119,478 by MPM Oncology Innovations\nFund, L.P. (\"MPM Oncology\") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. (\"MPM Oncology Impact\"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and\nBV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing\nmember of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 341,709 by MPM Asset Management LLC (\"MPM AM\"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM."}],"balance_after":1655971,"source":{"system":"sec-edgar","filing":"0001231919-26-000057","document":"form4-01142026_110117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000123191926000057/form4-01142026_110117.xml","form_type":"4"}},{"id":980574,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":83230,"price":0.97,"value":80733.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology."}],"balance_after":4784111,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980573,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":57225,"price":0.87,"value":49785.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology."}],"balance_after":4867341,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980572,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":59277,"price":0.89,"value":52756.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,070 by MPM Asset Management LLC (\"AM LLC\"), 25,712 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,715 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 884 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,662 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,234 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology."}],"balance_after":4924566,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":985366,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":60917,"price":0.94,"value":57261.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology."}],"balance_after":4983843,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985365,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":20277,"price":0.99,"value":20074.23,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology."}],"balance_after":5044760,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985364,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":60733,"price":0.98,"value":59518.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,170 by MPM Asset Management LLC (\"AM LLC\"), 26,343 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,757 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 907 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,801 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,755 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology."}],"balance_after":5065037,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":989048,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":42533,"price":0.92,"value":39130.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology."}],"balance_after":5125770,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":989047,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":88802,"price":0.98,"value":87025.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology."}],"balance_after":5168303,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":989046,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":64331,"price":0.83,"value":53394.73,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,417 by MPM Asset Management LLC (\"AM LLC\"), 27,904 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,861 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 960 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 6,145 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 23,044 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology."}],"balance_after":5257105,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":992831,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-20","kind":"sale","planned":true,"acquired":false,"shares":41152,"price":0.89,"value":36625.28,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of\nthe Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology."}],"balance_after":5321436,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":992830,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":66324,"price":0.94,"value":62344.56,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology."}],"balance_after":5362588,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":992829,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":52627,"price":0.93,"value":48943.11,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,613 by MPM Asset Management LLC (\"AM LLC\"), 22,827 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,523 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 786 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,027 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 18,851 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology."}],"balance_after":5428912,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":998125,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":57061,"price":0.95,"value":54207.95,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology."}],"balance_after":5481539,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":998124,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":61640,"price":0.93,"value":57325.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology."}],"balance_after":5538600,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":998123,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":90951,"price":0.98,"value":89131.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 6,244 by MPM Asset Management LLC (\"AM LLC\"), 39,450 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,631 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,359 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 8,688 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 32,579 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology."}],"balance_after":5600240,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":1002534,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-12","kind":"sale","planned":true,"acquired":false,"shares":40669,"price":1.09,"value":44329.21,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology."}],"balance_after":5691191,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002533,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":55810,"price":1.14,"value":63623.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology."}],"balance_after":5731860,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002532,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":48570,"price":1.18,"value":57312.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology."}],"balance_after":5787670,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002531,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-07","kind":"sale","planned":true,"acquired":false,"shares":68480,"price":1.11,"value":76012.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,702 by MPM Asset Management LLC (\"AM LLC\"), 29,704 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,981 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,022 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 6,541 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 24,530 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology."}],"balance_after":5836240,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1006039,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-06","kind":"sale","planned":true,"acquired":false,"shares":54452,"price":1.21,"value":65886.92,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology."}],"balance_after":5904720,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1006038,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":47950,"price":1.22,"value":58499.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology."}],"balance_after":5959172,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1006037,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":140488,"price":1.22,"value":171395.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 9,645 by MPM Asset Management LLC (\"AM LLC\"), 60,937 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,420 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 50,324 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology."}],"balance_after":6007122,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1009818,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":94063,"price":1.29,"value":121341.27,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology."}],"balance_after":6147610,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1009817,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-10-31","kind":"sale","planned":true,"acquired":false,"shares":114044,"price":1.28,"value":145976.32,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology."}],"balance_after":6241673,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1009816,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-10-30","kind":"sale","planned":true,"acquired":false,"shares":86936,"price":1.43,"value":124318.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,969 by MPM Asset Management LLC (\"AM LLC\"), 37,709 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 8,304 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 31,141 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology."}],"balance_after":6355717,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1012193,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":134240,"price":1.55,"value":208072.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology"},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology."}],"balance_after":6442653,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1012192,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":69068,"price":1.64,"value":113271.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology."}],"balance_after":6576893,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1012191,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-27","kind":"sale","planned":true,"acquired":false,"shares":72709,"price":1.72,"value":125059.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,992 by MPM Asset Management LLC (\"AM LLC\"), 31,538 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,945 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 26,045 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology."}],"balance_after":6645961,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1163512,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":false,"shares":42842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology."}],"balance_after":0,"derivative":{"exercise_price":0.09,"expiration_date":"2025-08-13","underlying":"Common Stock","underlying_shares":42842},"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163511,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":false,"shares":8031,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The warrants were held as follows:  3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology."}],"balance_after":0,"derivative":{"exercise_price":0.09,"expiration_date":"2025-04-09","underlying":"Common Stock","underlying_shares":8031},"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163510,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"sale","planned":false,"acquired":false,"shares":4386,"price":1.05,"value":4605.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6718670,"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163509,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":true,"shares":50873,"price":0.09,"value":4578.57,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 461,408 by MPM Asset Management LLC (\"AM LLC\"), 2,915,905 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 194,486 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 100,365 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 640,121 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 2,410,771 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology.  Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6723056,"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":2725321,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":12899925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"No securities held by the Reporting Persons."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1488033},"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725320,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":38817998,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B), 71,848 by AM BV2014, 457,643 by MPM OIF and 1,721,669 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"No securities held by the Reporting Persons."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4477742},"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725319,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":245000,"price":16,"value":3920000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B), 3,931 by AM BV2014, 25,040 by MPM OIF and 94,201 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 461,408 by AM LLC, 2,895,235 by BV 2014, 193,108 by BV 2014(B), 99,655 by AM BV2014, 634,766 by MPM OIF and 2,388,011 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6672183,"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725318,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1488033,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 461,408 by AM LLC, 2,781,025 by BV 2014, 185,490 by BV 2014(B), 95,724 by AM BV2014, 609,726 by MPM OIF and 2,293,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6427183,"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725317,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":4477742,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 461,408 by MPM Asset Management LLC (\"AM LLC\"), 2,087,358 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 139,224 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 71,848 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 457,643 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 1,721,669 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of AM LLC and a Managing Director of BV LLC. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P.  Ansbert Gadicke is the managing director of Oncology GP LLC.  Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":4939150,"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}}]}